• By ICR Secretariat
  • Posted Monday, August 3, 2020

5 FDA approval decisions to watch in the 3rd quarter

https://www.biopharmadive.com/news/fda-approval-decisions-third-quarter-2020/581169/

The next few months could bring the first gene therapy for hemophilia, a new type of multiple myeloma drug and an additional treatment option for a devastating muscular condition.

The Food and Drug Administration is set to make decisions on approval of all three, as well as on a closely watched arthritis pill and the first oral drug for spinal muscular atrophy, between July and September.